CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand

U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two FDA-Approved Anti-Rabies Immunoglobulin Products in the U.S. Market Estimated at $200 Million Annually Kamada's Manufacturing Capacity and Supply Availability Positioned to Support Increased Demand REHOVOT, Israel, and HOBOKEN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

GlobeNewsWire • Sep 17, 2026

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel.

GlobeNewsWire • Sep 10, 2026

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders

REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA”) with respect to the cash dividend of $0.17 (approximately NIS 0.51) per share on the Company's ordinary shares (totaling approximately $9.8 million) announced on August 17, 2026 (the “Dividend”), expected to be paid on September 17, 2026 (the “Payment Date”), to shareholders of record at the close of business on August 27, 2026 (the “Record Date”).

GlobeNewsWire • Sep 3, 2026

AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be The Cure

For investors seeking opportunities outside the AI trade, healthcare stocks can offer diversification without sacrificing exposure to growth. S&P 500 healthcare earnings are projected to rise by 22% YoY in 2027, the second-highest estimated growth rate among the eleven sectors, topped only by technology. According to JPMorgan analysts, at a time when many investors remain highly concentrated in the AI theme, healthcare offers a rare combo of durable growth, tech-like margins, and value.

Seeking Alpha • Sep 1, 2026

Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026

Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consistent with the Company's Cash Dividend Policy

GlobeNewsWire • Aug 17, 2026

Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet

The consensus price target hints at a 79.1% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Aug 14, 2026

Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research • Aug 14, 2026

KMDA or PRTA: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Aug 14, 2026

Should Value Investors Buy Kamada (KMDA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Aug 13, 2026

Kamada Q2 Earnings Call Highlights

Kamada NASDAQ: KMDA reported record revenue and adjusted EBITDA for the second quarter and first half of 2026, driven by higher sales of its specialty plasma-derived products, including KEDRAB, VARIZIG and HEPAGAM. The company reiterated its full-year guidance and said it expects initial sales under a new plasma supply agreement to begin in the fourth quarter.

MarketBeat • Aug 12, 2026